Brazil suspends Bharat Biotech's Covaxin clinical trials

Brazil has suspended the clinical studies of Bharat Biotech's COVID-19 vaccine, Covaxin following termination of the company's agreement with its partner there, the South American Country's......

Bharat Biotech's nasal vax priced at Rs 800 for private markets

Bharat Biotech International Limited on Tuesday said its COVID-19 intranasal vaccine iNCOVACC, which is now available on CoWIN portal, is priced at Rs 800 (excluding GST) for private markets and Rs......

Bharat Biotech's nasal Covid vaccine iNCOVACC launched

Union Health Minister Mansukh Mandaviya and Science and Technology Minister Jitendra Singh launched Bharat Biotech's nasal Covid vaccine, iNCOVACC, on the occasion of Republic Day on Thursday.......

'Big Boost': Bharat Biotech's nasal vaccine against Covid cleared for use

The Drugs Controller General of India (DCGI) on Tuesday approved Bharat Biotech's intranasal Covid vaccine for restricted emergency use in those aged above 18 years. "Big Boost to India's Fight......

Biotech revolution: 12 novel projects

Department of Biotechnology is considering 12 novel research projects, initiated by leading bitechnology companies, in the country under the second round of Small Business Innovation Research......

Markets ended flat amid a volatile trading session

The markets ended flat amid a volatile trading session on Monday after elections for the 16th Lok Sabha kicked off today. Meanwhile, Sun Pharma and Ranbaxy Labs hogged the limelight after Sun......

PE not for small-ticket HNIs

Bharat Banka, Managing Directorand CEO, Aditya Birla Private Equity, is delighted with high net-worth individuals' rising interest in private equity. With expected returns of 25-30 per cent......

'Few FCCB re-pay options for India Inc'

Only five Indian companies would be in a position to choose most available redemption options for their foreign currency convertible bonds (FCCBs), due for redemption this year, according to a......